Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCD | Q05655 | 18/20 | 1.00 |
| ▸ | PRKCA | P17252 | 12/20 | 1.00 |
| ▸ | PRKCG | P05129 | 10/20 | 1.00 |
| ▸ | PRKCB | P05771 | 9/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 9/20 | 1.00 |
| ▸ | PRKCH | P24723 | 8/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 8/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 3/20 | 1.00 |
| ▸ | PRKCI | P41743 | 2/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indolactum SCHEMBL29375485 | 1.00 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| Indolactum SCHEMBL1278694 | 1.00 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL25138542 | 0.90 | PRKCD (0.81) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL26998373 | 0.87 | PRKCD (0.77) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL29885447 | 0.87 | PRKCD (0.76) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL31662410 | 0.83 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL25138772 | 0.83 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL30010317 | 0.83 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL29783196 | 0.82 | PRKCD (0.78) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL30010733 | 0.77 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150240213-A1 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF DEFINITIVE ENDODERM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-8927280-B2 | Compositions and methods for promoting the generation of definitive endoderm | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140024114-A1 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF DEFINITIVE ENDODERM | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-23 | — | — | US | disclosed |
| US-8507274-B2 | Compositions and methods for promoting the generation of definitive endoderm | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120088300-A1 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF DEFINITIVE ENDODERM | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010091241-A2 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF DEFINITIVE ENDODERM | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088300-A1 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF DEFINITIVE ENDODERM | ALPG, PROX1, HNF4A | PRKCD 1337/4885PRKCA 1326/4885PRKCG 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.